
SWISS-MODEL is a widely used, fully automated homology (comparative) modelling server and workspace for predicting 3D protein structures. In pharmaceutical industry, it's especially valuable in early & mid stages: target validation, mutational analysis, guiding design in biotherapeutics, and supporting virtual screening.
1. Template search (via BLAST, HHblits) in the template library (SMTL).
2. Sequence-template alignment.
3. Model building (rigid fragment assembly) and energy minimization.
4. Model quality assessment (e.g. QMEAN) for both whole model and per-residue quality.
| Use Case | How SWISS-MODEL Is Applied | Benefit |
| Target Structure Prediction | When you have only sequence of a potential drug target, SWISS-MODEL can produce a 3D structure using templates. Even for targets without full experimental structure, model gives approximate binding pockets. | Enable early-stage structure-based drug design, virtual screening, and prioritization of targets. |
| Mutation Effect & Variant Modeling | Modeling different variants (e.g. point mutations) on a known scaffold to see effect on stability, binding interfaces, or structural integrity. | Help understand disease mutations or design more stable / effective biologics. |
| Ligand / Cofactor / Metal Ion Placement | If templates contain cofactors or metal ions, SWISS-MODEL can transfer those where alignment supports it. | Critical for enzymes or metalloproteins where cofactor binding is essential for function. |
| Complexes / Quaternary Structure Modeling | Modeling homo- or heteromeric assemblies when templates for complexes exist. Useful for receptors, multi-subunit enzymes, antibody complexes. | Useful for drugs targeting interfaces, for biologics, or understanding protein-protein interactions. |
| Model Validation & Quality Checking | Using QMEAN and other metrics to validate model reliability. Users can compare alternate templates and do manual alignment tweaks where needed. | Ensure models used in downstream work (e.g. docking, lead design) are reliable, reducing wasted effort. |
| Support in Structure-Based Drug Design (SBDD) | Models feed into docking studies, Virtual Screening, identification of binding pockets. Even approximate models often useful if high-identity templates exist. | Accelerate lead discovery, enzyme inhibitor design, antibody binding site analysis. |
| Understanding Pathogenic Mutations and Mechanism | Modeling human disease variants to see structural changes, e.g. destabilization or loss of binding sites. | Support drug target validation, disease mechanism studies, genetic diagnostics. |
Structure Modeling Service
Antibody-Antigen Interaction Modeling Service
Nucleic Acid Binding Protein Modeling Service
Peptide Folding Simulation Service
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk